Understanding how antibodies can protect against Brucella infections
Official title: Antibody Mediated Immunity Against Brucella
Funded at University of Missouri-Columbia · NIH-10950094 · Data updated 2026-11-12
This study is looking at how our immune system responds to a germ called Brucella, which can cause long-lasting infections, and it aims to find ways to make vaccines better at protecting us from this infection by understanding how they work in our bodies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | July 25, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $193,930 |
| NIH project number | 1R21AI185488-01 |
| Project ID | NIH-10950094 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of brucellosis, particularly those in contact with livestock or in regions where the disease is prevalent.
✕Less likely to help
Patients who are not at risk for brucellosis or those who have already been vaccinated against it may not benefit from this research.
What this research studies
This research investigates the immune response to Brucella, a bacterium that can cause lifelong infections in humans and animals. It aims to understand how antibodies produced by vaccines can alter the metabolism of host tissues to provide protection against this infection. The study will explore the mechanisms by which Brucella evades the immune system and how current vaccines can be improved to enhance their effectiveness. By identifying these processes, the research seeks to contribute to the development of better vaccines for preventing brucellosis.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines to prevent brucellosis in humans and animals.
How similar studies have gone: Previous research has shown promise in understanding antibody responses to infectious diseases, but this specific approach to Brucella immunity is relatively novel.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Ateya, Mostafa F — University of Missouri-Columbia
- Study coordinator: Ateya, Mostafa F
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
Understanding cell-cleanup problems in C9ORF72-related ALS/FTD
Researchers are studying why the body's cell-cleanup systems fail in a genetic form of ALS/FTD to pave the way for better treatments.
-
Molecular clues to endometriosis-related infertility
This grant explores how molecular changes in endometriosis contribute to infertility, with the aim of finding better ways to diagnose and treat the condition.
-
A universal Shigella vaccine using SAVE to protect people of all ages
A new vaccine approach called SAVE aims to prevent Shigella-related dysentery across all ages, including children and adults, by targeting conserved bacterial components.
-
Biomarkers that predict osteoarthritis risk in people at higher risk
A long-term study will look for protein markers in body fluids that could predict who will develop knee osteoarthritis before symptoms appear.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.